Literature DB >> 31760537

Recent advances steer the future of systemic sclerosis toward precision medicine.

Gemma Lepri1, Michael Hughes2,3, Cosimo Bruni1, Marco Matucci Cerinic1, Silvia Bellando Randone4.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31760537     DOI： 10.1007/s10067-019-04834-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  28 in total

1.  Senescence Signature in Skin Biopsies From Systemic Sclerosis Patients Treated With Senolytic Therapy: Potential Predictor of Clinical Response?

Authors:  Viktor Martyanov; Michael L Whitfield; John Varga
Journal:  Arthritis Rheumatol       Date:  2019-09-02       Impact factor: 10.995

Review 2.  What is precision medicine?

Authors:  Inke R König; Oliver Fuchs; Gesine Hansen; Erika von Mutius; Matthias V Kopp
Journal:  Eur Respir J       Date:  2017-10-19       Impact factor: 16.671

3.  Association of radiographic findings in hand X-ray with clinical features and autoantibodies in patients with systemic sclerosis.

Authors:  Komei Sakata; Yuko Kaneko; Hidekata Yasuoka; Tsutomu Takeuchi
Journal:  Clin Rheumatol       Date:  2019-06-18       Impact factor: 2.980

4.  Clinical and laboratory features of African-Brazilian patients with systemic sclerosis.

Authors:  Cristiane Mendes; Vilma S T Viana; Sandra G Pasoto; Elaine P Leon; Eloisa Bonfa; Percival D Sampaio-Barros
Journal:  Clin Rheumatol       Date:  2019-05-07       Impact factor: 2.980

5.  Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin.

Authors:  Monique Hinchcliff; Diana M Toledo; Jaclyn N Taroni; Tammara A Wood; Jennifer M Franks; Michael S Ball; Aileen Hoffmann; Sapna M Amin; Ainah U Tan; Kevin Tom; Yolanda Nesbeth; Jungwha Lee; Madeleine Ma; Kathleen Aren; Mary A Carns; Patricia A Pioli; Michael L Whitfield
Journal:  J Invest Dermatol       Date:  2018-01-31       Impact factor: 8.551

6.  Isolated DLco/VA reduction in systemic sclerosis patients: a new patient subset?

Authors:  Patricia Corzo; Anna Pros; Juana Martinez-Llorens; Luis Molina; Stephanie Fenxi Ling; Eva Balcells
Journal:  Clin Rheumatol       Date:  2018-10-27       Impact factor: 2.980

7.  Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease.

Authors:  Matthew Moll; Romy B Christmann; Yuqing Zhang; Michael L Whitfield; Yu Mei Wang; Lisa Rice; Eric Stratton; Robert Lafyatis; Harrison W Farber
Journal:  J Scleroderma Relat Disord       Date:  2018-03-22

8.  Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies.

Authors:  Sarah A Pendergrass; Raphael Lemaire; Ian P Francis; J Matthew Mahoney; Robert Lafyatis; Michael L Whitfield
Journal:  J Invest Dermatol       Date:  2012-02-09       Impact factor: 8.551

9.  Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.

Authors:  Jamie N Justice; Anoop M Nambiar; Tamar Tchkonia; Nathan K LeBrasseur; Rodolfo Pascual; Shahrukh K Hashmi; Larissa Prata; Michal M Masternak; Stephen B Kritchevsky; Nicolas Musi; James L Kirkland
Journal:  EBioMedicine       Date:  2019-01-05       Impact factor: 8.143

10.  Molecular subsets in the gene expression signatures of scleroderma skin.

Authors:  Ausra Milano; Sarah A Pendergrass; Jennifer L Sargent; Lacy K George; Timothy H McCalmont; M Kari Connolly; Michael L Whitfield
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240
View more
  8 in total

1.  Lung magnetic resonance imaging in systemic sclerosis: a new promising approach to evaluate pulmonary involvement and progression.

Authors:  Luna Gargani; Cosimo Bruni; Daniele De Marchi; Chiara Romei; Serena Guiducci; Silvia Bellando-Randone; Giovanni Donato Aquaro; Alessia Pepe; Emanuele Neri; Stefano Colagrande; Fabio Falaschi; Alberto Moggi-Pignone; Alessandro Pingitore; Marco Matucci-Cerinic
Journal:  Clin Rheumatol       Date:  2020-11-07       Impact factor: 2.980

Review 2.  Mitochondria, Aging, and Cellular Senescence: Implications for Scleroderma.

Authors:  Marta Bueno; Anna Papazoglou; Eleanor Valenzi; Mauricio Rojas; Robert Lafyatis; Ana L Mora
Journal:  Curr Rheumatol Rep       Date:  2020-06-19       Impact factor: 4.592

3.  Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition.

Authors:  Cosimo Bruni; Maya H Buch; Daniel E Furst; Giacomo De Luca; Aleksandra Djokovic; Raluca B Dumitru; Alessandro Giollo; Marija Polovina; Alexia Steelandt; Kostantinos Bratis; Yossra Atef Suliman; Ivan Milinkovic; Anna Baritussio; Ghadeer Hasan; Anastasia Xintarakou; Yohei Isomura; George Markousis-Mavrogenis; Lorenzo Tofani; Sophie Mavrogeni; Luna Gargani; Alida Lp Caforio; Carsten Tschöpe; Arsen Ristic; Karin Klingel; Sven Plein; Elijah R Behr; Yannick Allanore; Masataka Kuwana; Christopher P Denton; Dinesh Khanna; Thomas Krieg; Renzo Marcolongo; Ilaria Galetti; Elisabetta Zanatta; Francesco Tona; Petar Seferovic; Marco Matucci-Cerinic
Journal:  J Scleroderma Relat Disord       Date:  2021-10-26

Review 4.  Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials.

Authors:  David Roofeh; Alain Lescoat; Dinesh Khanna
Journal:  Expert Opin Emerg Drugs       Date:  2020-10-26       Impact factor: 4.191

5.  Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes.

Authors:  Alain Lescoat; Susan L Murphy; David Roofeh; John D Pauling; Michael Hughes; Robert Sandler; François Zimmermann; Rachel Wessel; Whitney Townsend; Lorinda Chung; Christopher P Denton; Peter A Merkel; Virginia Steen; Yannick Allanore; Francesco Del Galdo; Dominique Godard; David Cella; Sue Farrington; Maya H Buch; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2020-10-05

6.  Gamma-oryzanol as a potential modulator of oxidative stress and inflammation via PPAR-y in adipose tissue: a hypothetical therapeutic for cytokine storm in COVID-19?

Authors:  Fabiane Valentini Francisqueti-Ferron; Jéssica Leite Garcia; Artur Junio Togneri Ferron; Erika Tiemi Nakandakare-Maia; Cristina Schmitt Gregolin; Janaina Paixão das Chagas Silva; Klinsmann Carolo Dos Santos; Ângelo Thompson Colombo Lo; Juliana Silva Siqueira; Letícia de Mattei; Bruno Henrique de Paula; Felipe Sarzi; Carol Cristina Vágula de Almeida Silva; Fernando Moreto; Mariane Róvero Costa; Ana Lucia A Ferreira; Igor Otávio Minatel; Camila Renata Corrêa
Journal:  Mol Cell Endocrinol       Date:  2020-11-28       Impact factor: 4.102

Review 7.  Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis.

Authors:  Theodoros-Ioannis Papadimitriou; Arjan van Caam; Peter M van der Kraan; Rogier M Thurlings
Journal:  Biomedicines       Date:  2022-01-29

Review 8.  The Use and Utility of Machine Learning in Achieving Precision Medicine in Systemic Sclerosis: A Narrative Review.

Authors:  Francesco Bonomi; Silvia Peretti; Gemma Lepri; Vincenzo Venerito; Edda Russo; Cosimo Bruni; Florenzo Iannone; Sabina Tangaro; Amedeo Amedei; Serena Guiducci; Marco Matucci Cerinic; Silvia Bellando Randone
Journal:  J Pers Med       Date:  2022-07-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.